Clinical Signals from NKore’s Allogeneic sNK Platform Demonstrating Safety, Persistence & Potential Therapeutic Benefit
- Advancing first-in-human safety, early compassionate-use cases show no adverse events in patients treated with NK101, supporting a favorable emerging safety profile ahead of IND submission
- Demonstrating NK-cell persistence and immune engagement, immune-monitoring data show NK-cell levels rising from <2% to ~18% post-infusion in one patient, indicating meaningful in vivo activity
- Informing clinical development and indication strategy, early real-world experience is guiding prioritization, dosing, and translational endpoints as NKore moves toward first-in-human trials